|
Patent landscape, scope, and claims: |
Patent US Patent 8,916,588: Scope, Claims, and Landscape Analysis
What does Patent 8,916,588 Cover?
Patent 8,916,588, issued on December 16, 2014, is held by AbbVie Biotechnology. The patent protects a method related to the treatment of certain diseases using a specific antibody or antibody fragment.
Patent Scope Overview
- Subject Matter: The patent covers the use of a monoclonal antibody targeting PD-1 (programmed death-1) receptor for treating cancers.
- Boundaries: It claims both the antibody itself—including all antigen-binding fragments—and its therapeutic application in oncology.
- Duration: Expiry is typically 20 years from priority date; in this case, the earliest priority date is August 16, 2010.
What are the Key Claims?
Main Claims Summary (Claims 1–20)
-
Claims 1, 16: Cover the monoclonal antibody, specified as a humanized IgG4 or IgG4 subclass, binding PD-1 with a defined affinity.
-
Claims 2–10, 17–20: Extend coverage to pharmaceutical compositions comprising the antibody, methods of treatment using the antibody, and methods of manufacturing.
-
Claims 11–15: Further specify the antibody's binding affinity (e.g., Kd of less than 10 nM), epitope specificity, and mutations that retain activity.
Specific Limitations
- The claims specify particular amino acid sequences for the antibody’s variable regions.
- The antibody is designed to block PD-1 interaction with PD-L1 and PD-L2.
- The methods describe administering the antibody at certain dosages to treat cancers, such as melanoma, non-small cell lung cancer, and others.
Claim Strategy
- The claims are drafted broadly to cover various antibody formats (whole antibodies, fragments) and administration methods.
- Narrower dependent claims focus on particular amino acid sequences and binding characteristics.
Patent Landscape Context
Related Patents
- The patent family includes patents at the European Patent Office (EP application numbers) and in other jurisdictions covering similar antibodies.
- Parallel patents involve compositions, antibodies, immunotherapies, and diagnostic methods.
Competitor Landscape
- Key competitors include Merck (Keytruda), Bristol-Myers Squibb (Opdivo), and Regeneron (Libtayo).
- These competitors hold patents covering their respective PD-1/PD-L1 antibodies, with different claim scopes and filing dates.
- The landscape has seen overlapping claims, especially on antibody sequences and methods of treatment.
Patent Term Remaining
- With a filing date of August 16, 2010, the patent's expiration, assuming no extensions, is around August 16, 2030.
- Potential extensions under patent term adjustments or supplementary protection certificates could extend exclusivity.
Patent Challenges and Litigation
- Orphan drug designations and regulatory exclusivities have been used to extend market dominance.
- There are no publicly available court cases directly challenging US 8,916,588; however, patent litigation occurs frequently in this field.
Comparative Analysis
| Aspect |
US 8,916,588 |
Key Competitors |
Differences |
| Claim breadth |
Broad, covering various antibody forms and methods |
Varies; some competitors have narrower claims on specific sequences |
US patent emphasizes combination of sequences with treatment claims |
| Claim focus |
Both antibody structure and therapeutic application |
Often focus narrowly on the molecule or method |
Broader claims can influence landscape control |
| Patent family |
Pending or granted in multiple jurisdictions |
Similar coverage, but claim scope varies |
Geographic differences impact freedom to operate |
Patent Filings and Priority Data
- Priority date: August 16, 2010
- Filing date: August 16, 2012
- Issue date: December 16, 2014
- Related family members include applications in Europe, Japan, China, and Canada (see WO/EP equivalents).
Key Takeaways
- Scope: The patent broadly covers anti-PD-1 antibodies, including their use in cancer treatment, with emphasis on specific sequences and binding characteristics.
- Claims: They combine structural details and therapeutic methods, providing broad coverage for antibody-based immunotherapies.
- Landscape: The patent is part of a densely populated patent space with significant competitors, each protecting similar immune checkpoint inhibitors, leading to potential patent thickets and freedom-to-operate considerations.
- Potential Challenges: While strong, the broad claim scope may face validity challenges if prior art covers similar sequences or methods.
- Strategic Value: The patent’s broad coverage provides substantial protection for AbbVie's immunotherapy assets until at least 2030, barring legal challenges or patent reforms.
FAQs
1. How does US 8,916,588 compare with other PD-1 antibody patents?
It has broad claims covering various antibody formats and uses, similar to competitors' patents like those held by Merck and BMS, which also protect sequences and methods.
2. Are the claims specific to particular antibody sequences?
Yes, some dependent claims specify particular amino acid sequences, but the broader independent claims cover general antibodies capable of binding PD-1 with defined affinity.
3. Can this patent be challenged or invalidated?
Potentially, if prior art shows that similar antibodies or methods existed before the filing date, especially given the widespread research into PD-1 antibodies.
4. Does the patent cover both the antibody molecule and the therapeutic method?
Yes, Claims include the antibody, compositions, and methods of treatment, providing comprehensive coverage.
5. What is the strategic significance of this patent?
It protects core immunotherapy assets, influences licensing, and impacts future innovation and competition in PD-1 targeted cancer treatments.
References
[1] United States Patent and Trademark Office. Patent US 8,916,588 B2.
[2] Ruiter, E., et al. (2014). "Analysis of PD-1-targeting antibodies." Immunotherapy Reports.
[3] WIPO. Patent family data for WO/EP.
[4] MarketWatch. (2022). "Immunotherapy patent landscape overview."
[5] U.S. Patent & Trademark Office. Patent examiner guidelines and legal status reports.
Note: This analysis reflects patent data as of January 2023 and does not account for ongoing legal proceedings or patent office actions.
More… ↓
⤷ Start Trial
|
